Neurocrine Biosciences Plans First Quarter Earnings Call

Author: Evelyn Baker Updated: 04-14-2025 04:12 PM

Neurocrine Biosciences' Upcoming Conference Call Agenda

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) is gearing up for an important announcement regarding its first quarter 2025 financial results. The company will host a conference call and webcast designed to keep investors and the public informed about its financial performance.

Details of the Conference Call

This financial results call is set for 1:30 p.m. Pacific Time on a designated day in May. Prior to this call, the related press release will be disseminated at 1:00 p.m. Pacific Time, allowing stakeholders to review the company’s earnings report in advance.

How to Participate in the Webcast

Interested participants can access the conference call through the Neurocrine Biosciences website. Following the live event, a replay will be available on their site, ensuring that those unable to attend the call can still catch up on the vital information presented.

Dial-in Information

For those wishing to call in, the domestic dial-in number is readily available, along with an international option for global participants. During the call, listeners will be able to gain insights into the company’s strategic direction and financial performance.

Insights into Neurocrine Biosciences

Neurocrine Biosciences is dedicated to advancing neuroscience and improving lives. With a steadfast focus on developing treatments for complex neurological and neuropsychiatric conditions, the company has built a robust portfolio that includes FDA-approved therapies. Their efforts reach individuals affected by tardive dyskinesia, chorea from Huntington's disease, and various other serious health issues.

Innovative Treatments in Development

The firm is not only invested in current therapies but is also exploring new avenues with a pipeline rich in late-phase clinical programs. This commitment underscores their mission to discover transformative solutions for patients in desperate need of effective treatments.

The Commitment to Patients

At the core of Neurocrine Biosciences' mission is the promise to relieve suffering. Their unique capabilities in neuroscience inspire a relentless pursuit of breakthroughs that will enhance the quality of life for individuals dealing with debilitating disorders.

Global Outreach and Collaboration

Through collaborations and partnerships, including efforts in association with AbbVie, the company continues to extend its reach in the biopharmaceutical landscape. Their focus on collaboration highlights the importance of pooling expertise to better address the needs of those they serve.

Frequently Asked Questions

What date is Neurocrine’s earnings conference call?

The earnings conference call is scheduled for May 5, 2025, at 1:30 p.m. Pacific Time.

How can I access the conference call?

Participants can access the call via the Neurocrine Biosciences website, where a replay will also be made available shortly after the event concludes.

What is Neurocrine Biosciences focused on?

Neurocrine Biosciences is focused on developing life-changing treatments for neurological and neuropsychiatric disorders.

What are some approved treatments from Neurocrine?

The company’s portfolio includes approved treatments for conditions like tardive dyskinesia and chorea associated with Huntington's disease.

What is Neurocrine's mission?

Neurocrine's mission is to relieve suffering for individuals with severe health conditions through innovative research and treatment developments.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.